Rapport Therapeutics (NASDAQ:RAPP) Stock: Insider Wendy Young Purchases 3,789 Shares

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Director Wendy Young acquired 3,789 shares of the business’s stock in a transaction on Thursday, October 22nd. The shares were purchased at an average price of $26.39 per share, with a total value of $99,991.71. Following the completion of the purchase, the director owned 13,289 shares in the company, valued at $350,696.71. This represents a 39.88% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.

Rapport Therapeutics Price Performance

Shares of Rapport Therapeutics stock opened at $25.93 on Friday. The business has a 50 day simple moving average of $39.01 and a two-hundred day simple moving average of $38.93. Rapport Therapeutics, Inc. has a 12 month low of $23.75 and a 12 month high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). On average, research analysts predict that Rapport Therapeutics, Inc. will post -4.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Rapport Therapeutics

A number of institutional investors have recently added to or reduced their stakes in RAPP. Sterling Capital Management LLC boosted its stake in Rapport Therapeutics by 597.9% during the third quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock worth $33,000 after buying an additional 843 shares during the last quarter. Engineers Gate Manager LP purchased a new stake in Rapport Therapeutics in the 2nd quarter valued at $888,000. Wellington Management Group LLP grew its holdings in Rapport Therapeutics by 11.2% in the 2nd quarter. Wellington Management Group LLP now owns 86,988 shares of the company’s stock valued at $3,625,000 after buying an additional 8,757 shares in the last quarter. Artia Global Partners LP acquired a new stake in shares of Rapport Therapeutics in the 2nd quarter worth $5,772,000. Finally, Bank of America Corp DE acquired a new stake in shares of Rapport Therapeutics in the 2nd quarter worth $3,170,000.

Rapport Therapeutics News Roundup

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 met both Phase 2 endpoints in bipolar mania. The drug delivered statistically significant placebo-adjusted improvements in mania scores, and Rapport plans to advance it into Phase 3. Success could expand RAP-219’s opportunity beyond epilepsy and materially increase the company’s pipeline value. Rapport Therapeutics Phase 2 results
• Positive Sentiment: Analysts remain optimistic and raised price targets. JonesTrading lifted its target to $82, BTIG to $89 and Raymond James to $86, while HC Wainwright maintained a Buy rating. The reported consensus target of approximately $68.36 implies substantial upside from recent levels. Rapport Therapeutics analyst price target
• Positive Sentiment: Multiple insiders bought shares on the open market. CFO Troy Ignelzi purchased 5,500 shares, while directors Steven Paul, John Maraganore, Wendy Young, Paul Silva and Ramiro Sanchez also bought shares. The purchases totaled roughly $1.8 million based on the disclosed transactions and may signal management confidence following the clinical update. Rapport Therapeutics insider buying
• Neutral Sentiment: An analysis suggested Rapport could be significantly below estimated fair value following the Phase 2 results, but that valuation depends on successful Phase 3 development, regulatory approval and eventual commercialization.
• Negative Sentiment: Investors may have viewed the clinical win as less decisive than hoped. Reports indicated that some portions of the data only narrowly met expectations, potentially prompting profit-taking after the initial rally. Rapport bipolar mania data analysis
• Negative Sentiment: Rapport remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss missed analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. CEO Abraham Ceesay also sold 2,210 shares, a relatively small reduction of 0.49% in his holdings, which contrasts with the broader insider buying. SEC CEO ownership filing

Wall Street Analysts Forecast Growth

RAPP has been the subject of a number of research reports. Wall Street Zen lowered shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. HC Wainwright reissued a “buy” rating and issued a $66.00 price target on shares of Rapport Therapeutics in a research note on Tuesday. UBS Group began coverage on shares of Rapport Therapeutics in a research report on Thursday, October 15th. They set a “buy” rating and a $71.00 price target on the stock. William Blair assumed coverage on shares of Rapport Therapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating on the stock. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $86.00 price objective on shares of Rapport Therapeutics in a research note on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $68.36.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.